We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Different Genetic Features Associated With Hepatic Carcinogenesis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01247506
Recruitment Status : Unknown
Verified November 2010 by National Taiwan University Hospital.
Recruitment status was:  Recruiting
First Posted : November 24, 2010
Last Update Posted : November 24, 2010
National Science Council, Taiwan
Information provided by:
National Taiwan University Hospital

Brief Summary:
The purpose of this study is to identify different genetic features in hepatocellular carcinoma. It will assist in predicting individual risks of disease progression and would help to clarify pathophysiological mechanisms of HCC.

Condition or disease
Hepatocellular Carcinoma

Detailed Description:

Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths in Taiwan. HCC normally develops as a consequence of underlying liver disease and is most often associated with cirrhosis. Surgical resection and liver transplantation are current best curative options to treat HCC. However, recurrence or metastasis is quite common in patients who have had a resection and survival rate is 30% to 40% at 5 years postoperatively.

MicroRNAs, small non-coding RNA, act as endogenous RNA interference by post-transcription regulation. Recent studies suggest that microRNAs may act as tumor suppressors or oncogenes and altered microRNA expression levels may play an important role in the cancer initiation and progression. Several studies, including ourselves, have shown that specific microRNAs are aberrantly expressed in malignant HCC tissues compared to normal counterpart. Although many microRNA profiling studies were done to diagnose hepatocarcinogenesis, data about prognostic significances for postsurgical survival are very limited. The main point of this study is to develop a predictive signature for postsurgical survival in HCC patients.

Study Type : Observational
Estimated Enrollment : 160 participants
Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Identification of Survival-related microRNAs in Hepatocellular Carcinoma
Study Start Date : February 2010
Estimated Primary Completion Date : July 2012
Estimated Study Completion Date : July 2012

tumor tissues of HCC patients
paired nontumor tissues of HCC patients

Biospecimen Retention:   Samples With DNA
HCC tissues and paired nontumor tissues

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   45 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
A total of 160 patients with histologically proven HCC were collected by Dr. Po-Huang Lee's Lab (The Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan)

Inclusion Criteria:

  • clinical diagnosis of hepatocellular carcinoma

Exclusion Criteria:

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01247506

Contact: Tzu-Min Hung, PhD 886-2-23123456 ext 65956 mean6722@ms65.hinet.net

National Taiwan University Hospital Recruiting
Taipei, Taiwan
Principal Investigator: Cheng-Maw HO         
Sponsors and Collaborators
National Taiwan University Hospital
National Science Council, Taiwan
Study Chair: Po-Huang Lee, PhD National Taiwan University Hospital

Responsible Party: Po-Huang Lee, Proferrsor, Department of sugery, National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT01247506     History of Changes
Other Study ID Numbers: 200912020R
First Posted: November 24, 2010    Key Record Dates
Last Update Posted: November 24, 2010
Last Verified: November 2010

Keywords provided by National Taiwan University Hospital:

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases